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Cytochrome bc1, a dimeric multi-subunit electron-transport protein embedded
in the inner mitochondrial membrane, is a major drug target for the treatment
and prevention of malaria and toxoplasmosis. Structural studies of cytochrome
bc1 from mammalian homologues co-crystallized with lead compounds have
underpinned structure-based drug design to develop compounds with higher
potency and selectivity. However, owing to the limited amount of cytochrome
bc1 that may be available from parasites, all efforts have been focused on
homologous cytochrome bc1 complexes from mammalian species, which has
resulted in the failure of some drug candidates owing to toxicity in the host.
Crystallographic studies of the native parasite proteins are not feasible owing to
limited availability of the proteins. Here, it is demonstrated that cytochrome bc1
is highly amenable to single-particle cryo-EM (which uses significantly less
protein) by solving the apo and two inhibitor-bound structures to 4.1 Å
resolution, revealing clear inhibitor density at the binding site. Therefore,
cryo-EM is proposed as a viable alternative method for structure-based drug
discovery using both host and parasite enzymes.
1. Introduction
Cytochrome bc1 (bc1) is an established drug target against
apicomplexan parasites, for example Plasmodium falciparum
(Nixon et al., 2013) and Toxoplasma gondii (Doggett et al.,
2012), which are the causative agents of malaria and toxo-
plasmosis, respectively. According to data from the World
Health Organization, the malaria infection rate has declined
by 41% since the turn of the century, but 212 million cases still
occurred globally in 2015 (World Health Organization, 2016).
T. gondii is involved in ten million cases of foodborne illness
annually. Moreover, T. gondii causes congenital toxoplasmosis
in190 000 infants per year following congenital transmission
(Torgerson & Mastroiacovo, 2013). bc1, which exists as a
multi-subunit heterodimer embedded in the inner mitochon-
drial membrane, is a validated drug target for both of these
apicomplexan parasites (Schägger et al., 1986). The subunit
composition of the complex can vary between species. For
instance, there are three subunits in bacteria (Berry et al.,
2004), ten subunits in yeast (Hunte et al., 2000) and 11 subunits
in vertebrates (Xia et al., 1997; Zhang et al., 1998). However,
all bc1 complexes have a catalytic core containing three
essential subunits: cytochrome b, cytochrome c1 and the
Rieske iron–sulfur protein (Yang & Trumpower, 1986). bc1 is
the central component of the mitochondrial electron-transfer
chain which is responsible for the electron flow from ubiquinol
to cytochrome c. This occurs via the oxidation of ubiquinol
and the reduction of ubiquinone in a process called the Q cycle
(Mitchell, 1976). The Q cycle takes place in the Qi and Qo
binding pockets within cytochrome b (Erecińska et al., 1972).
Ubiquinol is oxidized to ubiquinone in the oxidative (Qo) site,
with two protons released into the intermembrane space,
while ubiquinone binds to the reductive (Qi) site, where it is
reduced to ubiquinol and takes two protons from the matrix
(Mitchell, 1976). This process allows proton translocation
from the matrix space to the intermembrane space, thus
increasing the electrochemical gradient across the membrane.
The first bc1 structure from bovine mitochondria was
determined by X-ray crystallography at 3.0 Å resolution in
1997 (Xia et al., 1997). Since then, numerous crystal structures
of bc1 from various species have been reported, some with
improved resolution, for example bovine (2.1 Å; Huang et al.,
2005), chicken (2.7 Å; Hao et al., 2012), yeast (1.9 Å; Solmaz &
Hunte, 2008) and Rhodobacter (2.4 Å; Esser et al., 2008), thus
providing a more detailed understanding of the enzyme
mechanism and structure–function relationship.
In apicomplexan parasites, oxidized ubiquinone from bc1
is used by dihydroorotate dehydrogenase (DHODH) to
generate orotate, which is an essential intermediate in pyri-
midine biosynthesis (Painter et al., 2007). Therefore, inhibition
of bc1 leads to a collapse in pyrimidine production, causing
parasite death (Srivastava & Vaidya, 1999). Atovaquone is an
analogue of ubiquinone that shows the ability to act as a
competitive inhibitor at the Qo site of cytochrome bc1 (Fry &
Pudney, 1992). It has been widely used in combination with
proguanil (known as Malarone) for the treatment of uncom-
plicated malaria and its prevention (Shanks et al., 1998), and
atovaquone can also be used to treat toxoplasmosis (Pearson
et al., 1999). Point mutations within the Qo site have been
found in atovaquone-resistant strains of malaria (Srivastava et
al., 1999) and toxoplasmosis (McFadden et al., 2000) parasites,
and structural analysis confirmed that these mutations signif-
icantly reduce the antiparasite activity of atovaquone by
preventing it from binding to the Qo pocket (Birth et al., 2014).
Owing to the emergence of drug-resistant malaria, new
compounds with improved potency and pharmacokinetic
properties are urgently required for the eradication of malaria.
Based on atovaquone, a number of lead compounds, such as
4(1H)-pyridones (Bueno et al., 2012) and 4(1H)-quinolones
(Biagini et al., 2012), have been designed to target the Qo site
of apicomplexan parasites (Supplementary Fig. S1).
GSK932121 is a 4(1H)-pyridone lead compound that has been
found to be highly active against atovaquone-resistant
P. falciparum (Bueno et al., 2012), but failed in a first human
trial because of acute cardiotoxicity (Jiménez-Dı́az et al.,
2009). The root of this issue was exposed by the crystal
structure, which showed the unexpected binding of GSK932121
to the Qi site of bovine bc1 (Capper et al., 2015). 2-Pyridyl-
quinolones have been developed for antimalarial activity, with
a mechanism of dual inhibition of NADH:ubiquinone
oxidoreductase (PfNDH2) and bc1 (Pidathala et al., 2012;
Biagini et al., 2012). One quinolone, SCR0911, has been
reported to have improved solubility and metabolic stability,
with nanomolar activity against P. falciparum (Charoen-
sutthivarakul et al., 2015).
Structure-based drug-design (SBDD) programmes are
reliant upon high-resolution structures of the target protein
being solved (Renaud et al., 2016; Anderson, 2003). When
complexed with their natural substrate or an inhibitor mole-
cule, they can provide essential information for the design of
new compounds which are highly selective for their target.
Previously, this has been underpinned by X-ray crystallo-
graphy; however, owing to the recent advances in single-
particle cryo-electron microscopy (cryo-EM), an increasing
number of high-resolution structures have been determined,
therefore the technique has the potential to play a role in
SBDD programmes (Rawson et al., 2017). For example, a
2.3 Å resolution cryo-EM structure of inhibitor-bound human
p97 ATPase identified an allosteric inhibition mechanism that
enables a structural basis for cancer drug design (Banerjee et
al., 2016). Cryo-EM is particularly useful for more challenging
targets such as large macromolecular complexes, viruses and
membrane proteins, as illustrated by the Fab–RV-B14 complex
(2.26 Å resolution; Dong et al., 2017) and the membrane
protein TRPV1 (2.9 Å resolution; Gao et al., 2016). Membrane
proteins remain challenging to study using X-ray crystallo-
graphy as they face hurdles in overexpression, the quantity of
highly purified protein produced and the quality of the crystals
obtained (Carpenter et al., 2008). By requiring less sample for
structural characterization (micrograms instead of milli-
grams), cryo-EM can overcome these issues (Rawson et al.,
2016). Moreover, the structure of the mammalian mitochon-
drial respirasome supercomplex has recently been determined
to an overall resolution of 4.0 Å, which highlights how the
individual components in the electron-transport chain interact
with one another, which had not previously been seen
using X-ray crystallography (Wu et al., 2016; Guo et al.,
2017).
Here, we present a novel, co-crystal structure of SCR0911-
bound bovine bc1 (at 3.1 Å resolution) and compare it with a
previously published crystal structure of the bovine bc1–
GSK932121 complex to discuss the differences in binding of
these two different families of inhibitors. Moreover, we then
show how cryo-EM has the potential to obtain structures at a
similar resolution at which it is possible to see strong inhibitor
density. By determining the cryo-EM structures of bovine apo
bc1, bc1–GSK932121 and bc1–SCR0911 to 4.1 and 4.4 Å
resolution, we can, for the first time, compare the information
obtained by cryo-EM and X-ray crystallography. The present
study demonstrates that cryo-EM could allow us to study the
bc1 complex in systems where the production of sufficient
quantities of native protein may be severely limiting for
crystallization.
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2. Methods
2.1. Preparation of bc1
bc1 was purified as described previously (Smith, 1967).
Briefly, bovine mitochondria were isolated from fresh bovine
hearts. The mitochondrial protein was quantified by the
bicinchoninic acid (BCA) assay (Smith et al., 1985) and solu-
bilized in 50 mM potassium phosphate pH 7.5, 250 mM NaCl,
0.5 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride with
the addition of 1 mg dodecylmaltoside (DDM) per 1 mg of
mitochondrial protein. The suspension was centrifuged at
200 000g for 1 h at 4C. The supernatant was loaded onto a
50 ml DEAE Sepharose CL6B (GE Healthcare) column pre-
equilibrated in and washed with three column volumes of
50 mM potassium phosphate pH 7.5, 250 mM NaCl, 0.5 mM
EDTA, 0.01% DDM and then eluted using a linear gradient
from 250 to 500 mM NaCl. bc1 fractions were pooled and
concentrated in a centrifugal ultrafilter (100 kDa molecular-
weight cutoff). The protein was loaded onto a 120 ml Sepha-
cryl S300 column (GE Healthcare) equilibrated in 20 mM
K-MOPS pH 7.2, 100 mM NaCl, 0.5 mM EDTA, 0.01% DDM
and eluted at a flow rate of 0.5 ml min1. bc1 fractions were
pooled and concentrated to a concentration of 40 mg ml1.
Increasing amounts of PEG 4000 were added stepwise to
precipitate bc1. The protein started precipitating at 2% PEG
4000, and pure cytochrome bc1 fractions were obtained
between 2.5 and 4% PEG 4000. The bc1 pellet was resolubil-
ized in 25 mM potassium phosphate pH 7.5, 100 mM NaCl,
0.5 mM EDTA, 0.015% DDM and then buffer-exchanged in a
centrifugal ultrafilter to remove residual PEG before being
adjusted to 5 mM. 50 mM inhibitor stock solution in DMSO
was added to a tenfold molar excess and incubated at 4C
overnight. The specific activity of cytochrome c reduction was
measured at 23C as described in Supplementary Table S1.
The specific activity of the purified bovine bc1 was
10.9 mmol min1 nM1 at 23C.
2.2. X-ray crystallography
The inhibitor-bound bc1 was mixed with 1.6% 6-O-(N-
heptylcarbamoyl)-methyl--d-glucopyranoside (HECAMEG)
and concentrated to 40 mg ml1. The protein solution was
mixed with an equal volume of reservoir solution (50 mM
potassium phosphate pH 6.8, 100 mM NaCl, 3 mM NaN3, 10–
13% PEG 4000). Crystals were grown by the hanging-drop
method at 4C. Bipyramidal red crystals appeared amongst
the precipitate after 2–3 d. Single crystals were harvested in
nylon loops, soaked stepwise in 50% ethylene glycol and
50 mM potassium phosphate pH 6.8, 100 mM NaCl, 3 mM
NaN3, 10–13% PEG 4000 and were then flash-cooled in liquid
nitrogen. The cooled crystals were tested for diffraction at
100 K using a home X-ray source at Barkla X-ray Laboratory,
University of Liverpool. The best diffracting crystals were sent
to the I03 beamline at Diamond Light Source, UK. A single
data set was collected with a PILATUS3 6M detector from a
crystal at 100 K using a wavelength of 0.98 Å. Data were
processed using iMosflm (Battye et al., 2011) and scaled using
AIMLESS (Evans & Murshudov, 2013). The structure was
solved by molecular replacement with MOLREP (Vagin &
Teplyakov, 2010) using the bc1 structure with PDB code 4d6u
(Capper et al., 2015) as the starting model; cofactors and
ligands were removed from the starting model. Jelly-body
refinement was carried out with REFMAC5 (Murshudov et al.,
2011) using the ProSMART option (Nicholls et al., 2014) to
assist low-resolution refinement during the first cycles of the
refinement. TLS parameters for each of ten chains were
introduced and refined at the final stages of the refinement to
reflect the different levels of flexibility of the chains. The
model was manually rebuilt in Coot (Emsley & Cowtan, 2004)
between refinement cycles. In addition to protein residues and
the inhibitor molecule, lipids (cardiolipin and 1,2-dimyristoyl-
sn-glycero-3-phosphocholine and 1,2-dihexanoyl-sn-glycero-
3-phosphoethanolamine) were added to the model, along with
DDM detergent, short fragments of PEG molecules and the
phosphate groups of less defined lipids. The inhibitor mole-
cules were produced by using JLigand (Lebedev et al., 2012).
Data collection and refinement statistics are shown in
Supplementary Table S2.
2.3. Electron microscopy
Purified bovine cytochrome bc1 was buffer-exchanged into
25 mM Tris pH 7.5, 100 mM NaCl, 0.5 mM EDTA and 0.015%
DDM or 0.01% lauryl maltose neopentyl glycol (LMNG) by
several dilutions in a centrifugal ultrafilter and adjusted to a
concentration of 5 mg ml1. 3 ml aliquots of the sample were
applied onto Quantifoil Cu R1.2/1.3 holey carbon grids, which
had been glow-discharged for 30 s using a Pelco glow-
discharge unit. An FEI Vitribot was used to blot the grids for
6 s (blot force 6) at 100% humidity and 4C before plunging
them into liquid ethane. The grids were loaded into an FEI
Titan Krios transmission electron microscope (Astbury
Biostructure Laboratory, University of Leeds) operating at
300 kV. Data were collected on a Falcon III direct electron
detector operated in integrating mode. Automated data
collection was performed using the EPU software, a defocus
range of 1 to 4 mm and a magnification of 75 000, which
yielded a pixel size of 1.065 Å for the two inhibitor-bound data
sets, which were collected with slightly different dose rates:
bc1–GSK932121 had a total dose of 75 e
 Å1 over a 1.5 s
exposure, whereas bc1–SCR0911 had a total dose of 85 e
 Å1
over a 2 s exposure. The apo bc1 data set was collected on a
Titan Krios operating at 300 kV at the Astbury Biostructure
Laboratory, which was fitted with a Gatan K2 electron
detector. Automated data collection was carried out using the
EPU software, a defocus range of 1 to 4 mm and a
magnification of 75 000, which yielded a pixel size of
1.047 Å. The total dose was 44 e Å1 over a 12 s exposure,
which was split into 20 frames (Supplementary Table S3). The
apo, GSK932121-bound and SCR0911-bound bc1 data sets
were collected over 3 d, resulting in 3256, 8840 and 7893
micrographs, respectively.
2.4. Image processing
All image processing was performed in RELION 2.0
(Scheres, 2012) unless otherwise stated. For all data sets the
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initial drift and CTF correction was carried out using
MotionCor2 (Zheng et al., 2017) and Gctf (Zhang, 2016),
respectively. For each data set, an initial subset of 2000
particles were manually picked and extracted into a 200  200
pixel box. These particles underwent two-dimensional classi-
fication to generate two-dimensional references to facilitate
auto-picking. The total numbers of particles picked for
GSK932121-bound, SCR0911-bound and apo bc1 were
466 865, 629 258 and 260 201, respectively, with the apo data
set having the smallest number of particles owing to it having
the fewest number of micrographs. For each data set, the
particles underwent an initial round of two-dimensional clas-
sification, with those classes that displayed clear secondary-
structure detail being taken forward to three-dimensional
classification and split into three classes. Two of the three
classes generated a high-quality bc1 reconstruction with
clearly visible secondary-structure information. The particles
from these two classes were recombined to form the final data
sets. For the apo bc1 data set 57 571 particles were three-
dimensionally refined using C2 symmetry to 4.4 Å resolution.
For the SCR0911 (114 130 particles) and GSK932121 (232 910
particles) inhibitor-bound data sets, a global resolution of
4.1 Å was obtained for each map. Further rounds of two- and
three-dimensional classification were performed on all of the
data sets, including using soft masks around different regions,
including the Rieske domain and the transmembrane region,
but the resolution and map quality did not improve. The
starting model for the reconstructions was a crystal structure
low-pass filtered to 60 Å. These models were also indepen-
dently generated ab initio in the absence of a starting model
using both RELION and cryoSPARC, resulting in an in-
distinguishable map from that seeded with a low-pass filtered
starting model (Scheres, 2012; Punjani et al., 2017). Existing
crystal structures were rigidly fitted into the maps using
UCSF Chimera (Pettersen et al., 2004) before MDFF (Trabuco
et al., 2010) was used to flexibly fit the model into the map. The
inhibitor-bound models underwent model relaxation in
Rosetta before being refined using PHENIX (Adams et al.,
2010). The maps were then inspected manually in Coot
(Emsley & Cowtan, 2004) and the model was corrected for any
errors in refinement and the placement of residues (Supple-
mentary Table S3). All figures were produced using
UCSF Chimera (Pettersen et al., 2004) or PyMOL (Schrö-
dinger).
2.5. Chemistry
The synthesis of SCR0911 was carried out as described by
Charoensutthivarakul et al. (2015).
3. Results
3.1. Crystal structure of inhibitor-bound bc1
The quinolone SCR0911 was co-crystallized with bovine bc1
in space group P6522 and data were collected to 3.1 Å reso-
lution. The resulting structure showed clear and continuous
density for most of the protein. The 6.4 kDa subunit 11 could
not be resolved within the structure; it may be lost during
purification or be too mobile to be resolved. bc1 structures
have been reported that show subunit 11 (Xia et al., 1997;
Esser et al., 2004) and these were purified using ammonium
sulfate precipitation protocols (Yu et al., 1974). For the
structures reported here, the protein was purified by DEAE
ion-exchange chromatography followed by gel filtration
(Iwata et al., 1998) with the addition of a PEG fractionation
step. Subunits 1, 2, 7, cytochrome b and cytochrome c1 (chains
A, B, F, C and D, respectively) are better defined in our
structure, while the Rieske protein has weaker electron
density and high temperature factors (the B factors for chains
E and I are given in Supplementary Table S2). Chain I, which
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Figure 1
Crystal structure of the Qi site of bovine bc1 with the SCR0911 inhibitor bound. (a) Cartoon representation of cytochrome b (blue) and the Rieske
protein (grey). The Qo and Qi sites of the cytochrome b subunit are highlighted in black boxes. Haems bL and bH are shown as blue sticks. Omit Fo  Fc
electron density (in green) is contoured at the 3 level, showing density for the SCR0911 inhibitor. (b) SCR0911 inhibitor bound in the Qi site. Residues
and inhibitor are shown as sticks. The 2Fo  Fc electron-density map is contoured at the 1 level, with the inhibitor density coloured green and the
protein density in purple. Hydrogen bonds between inhibitors and residues are illustrated by black dashed lines. (c) The crystal structures of the Qi site in
bc1–SCR0911 (purple) and bc1–GSK932121 (grey) have been superimposed, showing the different binding modes of the pyridone (GSK932121, grey)
and quinolone (SCR0911, purple) inhibitors.
corresponds to the truncated N-terminal part of the Rieske
protein, lacks the first 32 amino acids and adopts a confor-
mation closer to that defined in the stigmatellin- and anti-
mycin-bound bc1 structure (PDB entry 1ppj; Huang et al.,
2005). No additional density is seen within the Qo site,
suggesting that the quinolone solely inhibits the Qi site (Fig.
1a). There is additional density near haem bH in the Qi site
which is not accommodated by the protein, and its size and
shape allows unambiguous placement of the quinolone
compound SCR0911. After refinement, the compound fits well
into the 2Fo  Fc electron-density map (Fig. 1b), and its
temperature factors of75 Å2 are consistent with those of the
surrounding residues and are slightly higher than those of the
haem bH atoms (65 Å
2). The carbonyl and amine groups of
the quinolone head group are placed close to His201 and
Ser35 (at distances of 3.1 and 3.2 Å, respectively), allowing
hydrogen-bond formation. The bicyclic tail of SCR0911 is
placed away from haem bH towards the hydrophobic residue
Ile39. Crystal structure alignment of SCR0911-bound bc1 with
the previously determined structure of GSK932121-bound bc1
(PDB entry 4d6u; Capper et al., 2015) illustrates that both the
pyridone and quinolone compounds selectively inhibit the Qi
site but adopt different binding modes (Fig. 1c). There are
minor conformation changes in the Qi-site residues affected by
the inhibitors. The pyridone head of GSK932121 is flipped
over, forming hydrogen bonds between the carbonyl group
and Ser35 and between the 2-hydroxymethyl substituent and
His201 (Fig. 1c). For SCR0911, the head group of the quino-
lone forms two hydrogen bonds to the carbonyl group of
His201 and the amine group of Ser35. In other bovine bc1
crystal structures, His201, Ser35 and Asp228 make strong
interactions with ubiquinol (Gao et al., 2003) and Qi inhibitors,
including antimycin (Huang et al., 2005) and ascochlorin
(Berry et al., 2010). The hydrogen bonds to Ser35 and His201
contribute to the ability of SCR0911 and GSK932121 to tightly
occupy the Qi site and prevent the native substrate, ubiqui-
none, binding in the active site. The different binding inter-
actions of the head group result in the diaryl ether tail of
GSK932121 packing in a hydrophobic cavity defined by
Met190 and Met194. The bicyclic tail of SCR0911 is packed in
the hydrophobic pocket formed by Gly38 and Ile39, with its
trifluoromethyl group directed towards Ala232 (Fig. 1c).
These different binding modes of the pyridone and quinolone
inhibitors might influence the binding affinity to the bovine
enzyme. GSK932121 and SCR0911 were investigated for off-
target inhibition of bovine bc1 (Supplementary Table S1).
Single-point bc1 inhibition assays showed that SCR0911 has
significantly decreased binding for mammalian target than
GSK932121 at 100 nM: 9% inhibition compared with 64%.
The binding behaviour of SCR0911 in the bovine Qi site could
suggest a direction for the design of future lead compounds
with low affinity for mammalian bc1.
Although bovine and human cytochrome b show 80%
conservation, the conservation between human and
P. falciparum is only 40%. Surprisingly, the Qo site is the most
conserved region, with 65% conservation. The N-terminus of
the parasite cytochrome b, which constitutes half of the Qi site,
is four residues shorter and has 39% conservation in
comparison with mammalian homologues, leading to consid-
erable differences in the Qi binding site (Supplementary Fig.
S2), which may offer a way to rationally optimize lead
compounds to give more selective inhibitors of the parasite
enzyme. In the case of GSK932121, Met190 and Met194 are
replaced by Leu and Phe, respectively, in P. falciparum bc1,
which could be beneficial for the design of pyridone deriva-
tives. Interestingly, Ser35, which forms a hydrogen bond to the
quinolone molecule, is replaced by a bulky Phe residue that
would form a steric clash with SCR0911 in the parasite enzyme
if the binding modes were the same. Therefore, to bind within
P. falciparum bc1 SCR0911 must adopt a different binding
mode in the parasite enzyme to the mode observed in the
bovine crystal structure. Therefore, it is challenging to work on
improving the selectivity of the inhibitor without the experi-
mental structure of parasite bc1.
3.2. Structures of apo and inhibitor-bound bc1 from cryo-EM
We used cryo-EM to study the structure of bc1 in complex
with inhibitors from two different families with a pyridone
(GSK932121; Bueno et al., 2012) or quinolone (SCR0911;
Charoensutthivarakul et al., 2015) core, along with the apo
complex. The apo data set was resolved to a global resolution
of 4.4 Å and the two inhibitor-bound complexes were both
determined to 4.1 Å resolution as calculated by Fourier shell
correlation (FSC = 0.143; Scheres & Chen, 2012; Supple-
mentary Fig. S2). For all three maps the local resolution was
calculated using RELION (Figs. 2a, 2b and 2c), showing that
the core of the complex was resolved to a higher resolution
than the global average (4.2 Å for the apo bc1 map and 3.8–
4.0 Å for the inhibitor-bound maps). Moreover, the poorest
resolved region in each map was consistently the Rieske
protein, which was at 6 Å resolution in all maps. The iron–
sulfur cluster within this region is responsible for bifurcated
electron transfer from oxidation of ubiquinol in the Qo site to
cytochrome c1 in a bc1 catalytic cycle. Previously, it had been
reported that this domain is mobile and can exist in different
conformations (Iwata et al., 1998; Gao et al., 2003; Esser et al.,
2004, 2006). The other haem groups in the cryo-EM structure
of bc1 are the strongest features within the map. However, our
inability to resolve the iron–sulfur cluster, which should also
be a strong feature, leads us to conclude that it is mobile and
adopts different positions. Attempts to separate different
conformational states of the iron–sulfur cluster using soft
masks around the region were unsuccessful. This could suggest
that rather than being in distinct conformations, the Rieske
protein is more flexible but does not adopt multiple positions.
The resolution achieved allowed the modelling of -helices
and the location of haem groups and density that could be
attributed to -sheets. Moreover, there is density for the
larger, aliphatic/aromatic side chains in the transmembrane
region that can be modelled into the map (Figs. 2d, 2e and 2f).
At this resolution, de novo structure building is possible using
Rosetta, as exemplified by the CNG channel (James et al.,
2017). However, given that crystal structures were already
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Figure 2
The bovine bc1 structures determined by cryo-EM. Local resolution maps, coloured on the same scale, of (a) apo bc1, (b) bc1–GSK932121 and (c) bc1–
SCR0911, which show that the core of the complex is at the highest resolution and that the Rieske protein is the poorest resolved feature in the map. A
comparison of the map quality within each map (coloured grey, gold and cyan for the apo, GSK932121-bound and SCR0911-bound structures,
respectively) is shown for two representative transmembrane helices (d, e) and a -strand within the soluble domain ( f ). In (d)–( f ), the density was
contoured at 4, with the side chains being better resolved in the two inhibitor-bound structures.
available, these were docked into the corresponding cryo-EM
maps as an initial starting point, as the de novo building of bc1
would have been a significant undertaking. The docked crystal
structures were initially subjected to flexible fitting in MDFF
to identify any large changes at the secondary-structure level,
after which PHENIX was used to refine the side-chain posi-
tions (Adams et al., 2010). The maps were then visually
inspected to look for any areas of poor fit and the residues
were manually fitted, with the resulting structures being re-
refined in PHENIX. It is important to note that as we have the
phase information in the cryo-EM map, at no point in the
refinement procedure was the map modified or biased by the
fitted structure. Analysis of the resulting structures showed
there were no significant differences between the different
cryo-EM-derived structures and those solved by X-ray crys-
tallography, except for the Rieske domain (described below).
The Qi site in all three models has been analysed to
determine whether inhibitor density can be seen (Fig. 3). In
the apo structure there is weak density for the natural
substrate, ubiquinone, at the Qi site, which is consistent with
several studies that found ubiquinone bound to the Qi site
(Huang et al., 2005; Hao et al., 2012). Owing to the lower
resolution of the apo map, the side chains of the neighbouring
amino-acid residues could not be unambiguously modelled
into the density for all residues; however, many could be
placed into their approximate positions (Figs. 2 and 3). For the
two inhibitor-bound structures, there is clear inhibitor density
at the Qi site which does not appear at the Qo site, supporting
that these are selective Qi site inhibitors. The strongest inhi-
bitor density occurs in the bc1–SCR0911 map, where the
density for the compound is strong and comparable to that of
the neighbouring side chains (Fig. 3c). The density within the
Qi site suggests that SCR0911 adopts a conformation which is
consistent with the crystal structure. The quinolone head of
SCR0911 is placed between residues His201 and Phe220, and
the biaryl tail further extends into the hydrophobic region of
Ile39 and Ala232. In contrast, the density in the bc1–
GSK932121 map is strong for the pyridone head group but is
weaker at the tail of the molecule. The density also suggests
that there could be two binding poses of the compound caused
by rotation around the oxygen–carbon bond (as discussed in
more detail below). The Qi sites of the two inhibitor-bound
cryo-EM structures have been compared, showing a strong
agreement in the secondary structure of the protein. At 4.1 Å
resolution it is difficult to detect subtle changes in the posi-
tions of the amino-acid side chains which would result from
inhibitor binding. However, gross changes in the side-chain
position can be detected; for example, His201 shifts in position
between the two maps (Fig. 5a). For SCR0911, His201 is well
defined and is in a position consistent with hydrogen-bond
formation with the inhibitor, whereas the density for
GSK932121 suggests that there is no hydrogen-bond inter-
action with His201 and the density is more poorly defined
(Fig. 3). Comparisons of the Qi site of apo bc1 and inhibitor-
bound bovine bc1 in the cryo-EM structures shows that there
is no difference in the position of the -helices which surround
the active site, consistent with the observations from crystal
studies that show that no gross structural changes accompany
inhibitor binding.
3.3. Comparison of cryo-EM and X-ray crystallographic
structures
Owing to a lack of confidence in some side-chain positions,
we compared the main-chain C positions of the cryo-EM and
crystal structures of the bc1–SCR0911 complex, which resulted
in an r.m.s.d. of 0.5 Å. However, it should be noted that the
structure, especially in poorly defined areas of the map,
could still be biased by the original starting model used.
There is very high agreement between the protein core and
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Figure 3
Analysis of the Qi site in the three different cryo-EM maps with the density contoured at 3. (a) The Qi site in the apo bc1 cryo-EM map shows minimal
density (purple mesh) which does not correspond to any side chains or the haem bL group, suggesting noise within the map or that the natural substrate
ubiquinone is bound in a small number of bc1 molecules. (b) The Qi site in the cryo-EM map of bc1–GSK932121. The inhibitor density (green) suggests
there are two modes of inhibitor binding, accompanied by rotation around the oxygen–carbon bond. The binding pose shown in green agrees with the
crystal structure, with the trifluoromethyl group pointing towards Met194. There is additional density which suggests that the trifluoromethoxyphenyl
group could be rotated and point towards Asp228, revealing an additional mode of binding (shown in blue). (c) The Qi site in the cryo-EM map of bc1–
SCR0911, with the inhibitor shown in pink and located in strong density. The inhibitor is expected to make a hydrogen-bond contact with His201 and
strongly fits the density.
transmembrane domains. However, there are significant
differences in the mobile Rieske protein in the soluble region,
where the C r.m.s.d. value is greater than 2 Å (Fig. 4). This
observation correlates with the crystal structures of apo,
natural substrate-bound and Qo inhibitor-bound bovine bc1,
which capture different conformations of the Rieske protein
and suggest that the swivel motion of the Rieske protein
moves the 2S cluster closer to either the Qo site or the cyto-
chrome c1 haem to allow the transfer of one electron to
cytochrome c1 and one electron to the Qi site (Esser et al.,
2006). A number of different crystal structures of bc1 have
shown a range of positions for the Rieske protein (Iwata et al.,
1998; Gao et al., 2003; Esser et al., 2004, 2006; Xia et al., 2013;
Supplementary Fig. S4). The position of this protein can be
influenced by the space group in which the protein crystallizes
and the corresponding crystal contacts that are made
(Supplementary Fig. S4a), and the nature of the inhibitor
bound in the Qo site (Supplementary Fig. S4b). In the case of
the cryo-EM structures we have removed the influence of the
crystal lattice and therefore the Rieske domain is not being
influenced by the crystal contacts, and we note that the domain
does not adopt a large number of defined states, although its
resolution is significantly lower than that of the main body of
the protein, indicating a degree of flexibility (Fig. 4c). In the
cleaved N-terminal part of the Rieske protein (chain I resi-
dues 1–78), we can only see two -sheets assigned as the
C-terminal part of the fragment in the crystal structure.
Analysis of the Qi site of bc1–SCR0911 shows that the
ligand adopts a very similar position in the cryo-EM-derived
and X-ray-derived structures (Fig. 5). In both structures the
ligand can form hydrogen bonds to His201 and Ser35 on the
neighbouring helix. The Qi site amino acids adopt similar
positions in both structures, with an average C r.m.s.d. value
of 1.46 Å; there is a clear overlap of the -helices. There are
minor differences in the positions of the amino-acid side
chains, such as Phe220; however, this could be owing to the
difference in the resolutions of the two maps.
Examination of the Qi site in the bc1–GSK932121 cryo-EM
map suggested that the inhibitor binds in two different
conformations (Fig. 5b). Both binding modes have the pyri-
done head placed between haem bH and His201 and have the
diaryl tail group extending out of the hydrophobic channel
away from the haem group. The difference in the binding
conformations occurs at the 4-trifluoromethoxyphenyl ring of
the molecule, as there is rotation around the C—O bond which
results in two different binding positions (Fig. 3b). Pyridone
binding pose 1 has the trifluoromethoxy group from the
second aromatic ring pointing towards Met194. In comparison,
the cryo-EM structure has identified pyridone binding pose 2,
which shows the aromatic ring facing in the opposite direction
with the trifluoromethoxy group towards Asp228. Compar-
isons with the crystal structure reveal that the GSK932121
ligand adopts one binding position. As the additional binding
pose was not identified using crystallography, cryo-EM could
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Figure 4
Global comparison between cryo-EM-derived and X-ray-derived SCR0911-bound structures. (a) The cryo-EM and X-ray bc1–SCR0911 structures have
been overlaid and the crystal structure is coloured according to the calculated C r.m.s.d. value (low coloured cyan and high coloured maroon). The main
difference (r.m.s.d. of >2 Å) occurs for the Rieske domain (in the black square), which is known to be mobile during the catalytic cycle. (b) An overlay of
the Rieske domains in the cryo-EM-derived (cyan) and X-ray-derived (grey) bc1–SCR0911 structures. (c) The cryo-EM-derived map for the bc1–
SCR0911 structure with the Rieske domain fitted shown in the same orientation as in (a) and (b).
provide unique insights into alternative modes of binding and
occupancy of inhibitors.
3.4. Comparisons of isolated bc1 with the full respirasome
complex
The structure of the porcine respiratory supercomplex
(I1III3IV1) has been determined at 4.0 Å resolution (Wu et al.,
2016). After masking of the individual complexes the global
resolution of the map for the bc1 structure was improved to
3.6 Å, which could be owing to the protein being stabilized by
its interactions with the other components in the electron-
transport chain. In the full complex, no density was present at
either the Qi or Qo inhibitor-binding sites, which suggests that
there is no natural substrate present in this map.
Our cryo-EM-derived structure of isolated bc1–SCR0911
was compared with the bc1 map which was extracted from the
supercomplex cryo-EM map, with the largest differences being
found in the iron–sulfur cluster (Supplementary Fig. S5). The
crystal structure with the SCR0911 inhibitor bound was also
compared with the full respirasome complex. Interestingly, the
positions of the Rieske domains were similar when these two
models were compared (Supplementary Fig. S5b). This could
be a feature of the higher resolution of the two maps. More-
over, electron density is present in the supercomplex for
subunit 11 in bc1, which is not seen in either the X-ray or cryo-
EM structures of the isolated complexes owing to it being lost
during the purification procedure (Supplementary Fig. S5c).
4. Discussion and outlook
New medicines to treat malaria and other apicomplexan
diseases are urgently needed to deal with the growing burden
that these diseases place on many developing countries. A
promising approach to deal with this problem is through the
inhibition of bc1, which has been shown to be a validated
target against both Plasmodium and Toxoplasma, but
problems associated with drug resistance and toxicity must be
addressed. To achieve this, highly potent inhibitors have been
developed to target the Qi site. The inhibitor-binding mode
has been shown for some inhibitors by structural studies of the
bovine enzyme using X-ray crystallography.
The crystal structures reported here and previously have
been invaluable in providing insights into further inhibitor-
design and safety-profile improvement. However, a significant
limitation is the reliance upon a bc1 homologue which can be
extracted in the large milligram quantities required for crys-
tallization, with a concentration of 40 mg ml1 often being
required to obtain high-quality crystals. This prohibits the use
of native bc1 of parasite origin for crystallography as it cannot
be obtained in the high quantities required for crystallization.
Subsequently, alternative methods are required to solve the
structure of parasite bc1 at a resolution where inhibitor
binding can be seen but where the required level of protein is
significantly reduced. To this end, we provide the first single-
particle cryo-EM reconstructions for bovine bc1 in its apo
form and in complex with two inhibitors to show proof of
principle. The resolution of the cryo-EM map shows side-
chain density for bulky amino-acid residues but, without the
crystal structure to act as a guide. However, it would have
been a challenge to build the whole structure de novo. Despite
this, we can unambiguously identify the inhibitor-binding site
in the cryo-EM maps, and using chemical constraints such as
the presence of hydrogen bonds and/or in silico docking it is
possible to gain insights into the mode of binding. Moreover,
obtaining cryo-EM structures allows the protein to be solved
in its native state in the absence of any possible artefacts
owing to crystal contacts.
An advantage of X-ray crystallography over cryo-EM is the
resolution which is routinely achieved (often <2.5 Å), but the
timescale from purified protein through crystallization to
structure determination remains unpredictable. This is even
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Figure 5
Comparisons of the Qi site. (a) The cryo-EM structures of bc1–SCR0911 (cyan) and bc1–GSK932121 (gold) overlaid. The SCR0911 inhibitor is coloured
green and the GSK932121 inhibitor magenta. The overlay of the two structures shows there is no difference in the secondary-structure positions in the
two maps and only minor differences in the positions of the amino-acid residues. The largest difference occurs for His201, which forms a hydrogen bond
to SCR0911 but not GSK932121. (b) An overlay of the Qi site of bc1–GSK932121 in the cryo-EM (gold) and X-ray (purple) models. The density in gold
corresponds to the EM map, which shows a difference in the position of His201 compared with the X-ray structure. (c) An overlay of the Qi site of bc1–
SCR0911 in the cryo-EM (cyan) and X-ray (grey) models. There are no significant differences between the two models in either side-chain or secondary-
structure positions.
more challenging for membrane proteins, with crystallization
remaining one of the most unpredictable steps and often being
a bottleneck for many projects. For systems such as bc1 that
have been established in a laboratory, crystals can be grown
within 5 d after protein purification ready for data collection
at an advanced synchrotron crystallographic beamline, with
data collection, processing and initial model fitting taking
place in a single day. The current example demonstrates that
cryo-EM can be conducted in a similar timeframe but without
the uncertainty of obtaining diffraction-quality crystals or
requiring a large amount of purified protein. After obtaining a
purified bovine bc1 sample, the time taken from preparation of
the cryo-grids to obtaining a three-dimensional reconstruction
of the sample was less than 10 d. This timescale includes72 h
of data collection and a week of data processing, including the
initial motion-correction and classification steps. Although the
crystallization step is removed, it is important to note that grid
preparation and optimization is not without its own chal-
lenges. Given the rapid development in cryo-EM, particularly
in detector technology and image-processing speeds, as well as
the greater number of centres with high-quality microscopes,
this timescale is expected to become even shorter, making the
rapid screening of complex systems via cryo-EM a viable
alternative.
For systems where large quantities of purified protein can
be obtained, X-ray crystallography is likely to remain the gold-
standard approach for SBDD. For instance, in this study
bovine bc1 was purified and the resulting crystals diffracted to
3.1 Å resolution, which allowed the mode of inhibitor
binding to be established. However, by producing more
selective inhibitors, which no longer have high affinity for the
model system used for structural studies, alternative approa-
ches may be required. No structural data for the bc1 complex
from P. falciparum are available, thus hindering the current
SBDD programmes, which are based upon mammalian
homology models. Crystallography is not a viable route owing
to the large quantities of protein that are required and the
uncertainty that is imposed by crystallization. Based on the
current study, we propose that cryo-EM is a viable route for
studying large membrane-protein complexes from both the
host and, by analogy, the parasite, and their interactions with
bound inhibitors.
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Ibáñez, J., Alvarez-Doval, A., Shultz, L. D., Martı́nez, A., Gargallo-
Viola, D. & Angulo-Barturen, I. (2009). Antimicrob. Agents
Chemother. 53, 4533–4536.
research papers
IUCrJ (2018). 5, 200–210 Kangsa Amporndanai et al.  X-ray and cryo-EM structures of cytochrome bc1 209
Lebedev, A. A., Young, P., Isupov, M. N., Moroz, O. V., Vagin, A. A. &
Murshudov, G. N. (2012). Acta Cryst. D68, 431–440.
McFadden, D. C., Tomavo, S., Berry, E. A. & Boothroyd, J. C. (2000).
Mol. Biochem. Parasitol. 108, 1–12.
Mitchell, P. (1976). J. Theor. Biol. 62, 327–367.
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner,
R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011).
Acta Cryst. D67, 355–367.
Nicholls, R. A., Fischer, M., McNicholas, S. & Murshudov, G. N.
(2014). Acta Cryst. D70, 2487–2499.
Nixon, G. L., Pidathala, C., Shone, A. E., Antoine, T., Fisher, N.,
O’Neill, P. M., Ward, S. & Biagini, G. A. (2013). Future Med. Chem.
5, 1573–1591.
Painter, H. J., Morrisey, J. M., Mather, M. W. & Vaidya, A. B. (2007).
Nature (London), 446, 88–91.
Pearson, P. A., Piracha, A. R., Sen, H. A. & Jaffe, G. J. (1999).
Ophthalmology, 106, 148–153.
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S.,
Greenblatt, D. M., Meng, E. C. & Ferrin, T. E. (2004). J. Comput.
Chem. 25, 1605–1612.
Pidathala, C. et al. (2012). J. Med. Chem. 55, 1831–1843.
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. (2017).
Nature Methods, 14, 290–296.
Rawson, S., Davies, S., Lippiat, J. D. & Muench, S. P. (2016). Mol.
Membr. Biol. 33, 12–22.
Rawson, S., McPhillie, M. J., Johnson, R. M., Fishwick, C. W. G. &
Muench, S. P. (2017). Acta Cryst. D73, 534–540.
Renaud, J., Chung, C., Danielson, U. H., Egner, U., Hennig, M.,
Hubbard, R. E. & Nar, H. (2016). Nat. Rev. Drug Discov. 15, 679–
698.
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